

Contents

History, epidemiology and classification of PKU	13
1.1. Historical background.....	13
1.2. Epidemiology.....	15
1.3. Classification and nomenclature of PKU	15
The phenylalanine hydroxylating system	18
2.1. Phenylalanine hydroxylase (PAH).....	18
2.1.1. The phenylalanine hydroxylase system.....	18
2.1.2. Tetrahydrobiopterin.....	20
2.1.3. DNAJC12, a HSP40 co-chaperon of PAH.....	22
PKU due to phenylalanine hydroxylase deficiency	25
3.1. Physical characteristics of patients with PKU	25
3.2. Neurocognitive deficits in PKU	25
3.3. Candidate clinical mechanisms of neurocognitive deficits	28
3.4. Rationale for lifelong treatment of PKU to minimise neurological damage	30
3.5. Non-cerebral manifestations of (treated) PKU	30
3.6. Maternal PKU	30
3.7. Assessment of a patient with PKU	31
Tetrahydrobiopterin deficiencies	38
4.1. Overview	38
4.2. Clinical features.....	38
4.2.1. General clinical symptoms.....	38
4.2.2. Symptoms related to specific defects	39
4.3. Developmental outcomes.....	41
Diagnosis of hyperphenylalaninaemias	43
5.1. Newborn screening	43
5.1.1. History of newborn screening.....	43
5.1.2. Screening methods.....	44
5.1.3. General issues relating to screening.....	45
5.2. Differential diagnosis of PKU	45
5.2.1. Disorders of BH4 synthesis and recycling (BH4 deficiency)	45
5.2.2. BH4-responsive HPA/PKU.....	48
Dietary management of PKU	55
6.1. Aims of dietary management.....	55
6.2. Initiation of dietary therapy	55
6.3. Management guidelines	56
6.4. Monitoring	56
6.5. Delivery of treatment by the healthcare team.....	57
6.6. Transition of care	57
6.7. Application of dietary management	57

6.8.	Optimising growth and nutritional outcome	62
6.9.	Patient/caregiver education	62
6.10.	Gaining and maintaining dietary adherence	62
6.11.	Pregnancy and breastfeeding	66
6.12.	Alternative treatment options	66

Pharmacologic management of PKU with sapropterin dihydrochloride (BH4) 71

7.1.	The phenomenon of BH4 responsiveness	71
7.1.1.	Introduction to sapropterin/BH4	71
7.1.2.	Therapeutic indications for sapropterin	71
7.1.3.	Administering sapropterin	72
7.1.4.	Pharmacokinetics of sapropterin	73
7.2.	Therapeutic profile of sapropterin in general populations of patients with PKU	73
7.2.1.	Clinical efficacy	73
7.2.2.	Tolerability and safety in general populations of patients with PKU	76
7.2.3.	Neurophysiologic outcomes	76
7.2.4.	Quality of life	77
7.3.	Sapropterin in special populations of patients with PKU	77
7.3.1.	Children	77
7.3.2.	Pregnant women	77
7.3.3.	Patients with well-controlled blood Phe	78
7.4.	Adherence to sapropterin	78
7.5.	Future developments	78

Enzyme substitution therapy in PKU 82

8.1.	Rationale for enzyme replacement therapy within the management of PKU	82
8.2.	Human studies of pegvaliase	83

Gene therapy for PKU 88

9.1.	Experimental gene therapy for PKU using the classical "PKU" mouse model	88
9.2.	Overview of (planned) clinical trials	88

Management of tetrahydrobiopterin (BH4) deficiencies 91

10.1.	Overview	91
10.2.	First-line treatment	92
10.2.1.	Dietary treatment	92
10.2.2.	Tetrahydrobiopterin (sapropterin dihydrochloride)	94
10.2.3.	L-Dopa with or without carbidopa/benserazide	94
10.2.4.	5-Hydroxytryptophan	94
10.2.5.	Folinic acid	94
10.3.	Second-line pharmacologic treatment	95
10.3.1.	Dopamine agonists	95
10.3.2.	Monoamine oxidase inhibitors (MAOI; selegiline and rasagiline)	95
10.4.	Third-line treatment	95
10.4.1.	Chronic drug treatments	95
10.4.2.	Acute drug treatments	95
10.4.3.	Drugs to avoid in BH4 disorders	96
10.5.	Information from the BIODF database	96

	US phenylalanine hydroxylase deficiency diagnosis and management guideline	98
11.1.	Introduction	98
11.2.	Elements of the ACMG guideline	99
11.2.1.	Evidence Review	99
11.2.2.	Recommended Phe Level	99
11.2.3.	General recommendations	99
11.3.	Future issues	101
	European guidelines for the diagnosis and management of patients with phenylketonuria	103
12.1.	Introduction and background	103
12.2.	Overview of key recommendations	103
	Genetics of PKU and DNAJC12 deficiency	109
13.1.	Mendelian inheritance	109
13.2.	<i>PAH</i> genotype and severity of PKU	110
13.2.1.	Locations of variations in the <i>PAH</i> gene	110
13.2.2.	The PKU phenotype and severity of hyperphenylalaninaemia	110
13.2.3.	<i>PAH</i> genotype and BH4-sensitive PKU	112
13.3.	Genotypes associated with DNAJC12 deficiency	114
	Genetics of BH4 deficiencies	117
14.1.	Overview	117
14.2.	GTP cyclohydrolase I (<i>GCH1</i>)	117
14.3.	6-Pyruvoyl-tetrahydropterin synthase (<i>PTS</i>)	118
14.4.	Dihydropteridine reductase (<i>QDPR</i>)	118
14.5.	Sepiapterin reductase (<i>SPR</i>)	119
14.6.	Pterin-4a-carbinolamine dehydratase (<i>PCBD1</i>)	119
	Metabolomics research in Phenylketonuria (PKU)	121
15.1.	Background	121
15.2.	General problems in metabolomic analysis	121
15.3.	Application of metabolomics studies in PKU research	122
	Resources for patients and their families	126
16.1.	International PKU societies	126
16.2.	National PKU societies	126
16.3.	Online information sources	133
16.4.	Manufacturers and/or suppliers of special foods for use in PKU	134
16.5.	Books	134
	Abbreviations	135
	Index	136